Upon confirming that the G6P–AP‐1 axis enhanced Sln expression, we postulated that eliminating Sln levels might mitigate Dox‐treated Slc25a49‐deletion‐induced cardiomyopathy. This evidence concerns the gene FOS and cardiomyopathy.